

Cortellis Competitive Intelligence

Conference data in Cortellis


The Cortellis editorial team cover more than 100 conferences every year. These include partnering meetings such as BIO, JP Morgan and scientific conferences like American Society of Clinical Oncology (ASCO) and Annual European Congress of Rheumatology. Conferences are an excellent source of new information as well as updates on drugs, deals, companies and related data. Information is added to Cortellis within a couple of days following the conference.

This guide explains how to access conference reports from different areas in *Cortellis Competitive Intelligence*.


1. Links for recent and upcoming conference are found on the *Home page* in the *News* tile.

Like other reports in Cortellis, conference reports are indexed to make it easier for you to search and filter by date, indication or mechanism of action, for example.


Forthcoming meetings include a link to the conference website for registration and other details whereas past meetings include a link for a conference report in Cortellis.



2. Posters presented in conferences are summarized under *Presentations* on the results page.



3. Highlights from lectures and oral presentations are available in *Reports* on the results page. Overnight reports are written and published in *Cortellis Competitive Intelligence* within 12-24 hours after the event.



Conference *Reports* and *Presentations* are linked to drugs, companies and other reports mentioned in the event to help you quickly navigate to related information and investigate further.

Galectin-3 Inhibition by a Small-Molecule Inhibitor Downregulates Fibrosis-Related Genes and Signaling Pathways in a Mouse Model of Corneal Fibrosis

Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Editorial Abstract	SNAPSHOT
Title	Galectin-3 Inhibition by a Small-Molecule Inhibitor Downregulates F Corneal Fibrosis
Author	Author Block:Zhiyi Cao1 , Abdurraouf Ramadan1 , Fredrik Zetterberg2 , Noorjahan A. Panjwani1
Address	1 Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts, United States; 2 Galecto Biotech AB, Gothenberg, Sweden
Serial Publication	Annual Meeting of the Association for Research in Vision and Ophthalmology
Presentation Details	POSTER , Abs 1158
Conference	2021 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO)
Conference Dates	02-May-2021 - 06-May-2021
Conference Location	San Francisco, CALIFORNIA, US
Drugs	B-1265

Identify new drugs and read important updates on existing drugs in Cortellis Conference reports

4. Conference reports are also listed on the *Sources* tab in drug, deals and clinical trials and other reports.

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Protocol & Results	SOURCES
Subjects & Measurements	Press Releases Corporate Publications Serial Publications Conference Reports Clinical Trial Registries Other Publications
Registry Contacts & Sites	Results 1 - 1 of 1 Sort by Date: Ascending Descending
Change History	August 25-29, 2018
Sources	European Society of Cardiology (ESC) 2018 Congress - Part III - OVERNIGHT REPORT, Munich, Germany Puzzovio S SourceID: 2067196 View full report

Click 'View full report' to navigate to conference report cited as a source

5. Conference reports can also be retrieved using *Quick search* at the top of the screen when searching for drug and company names as well as mechanism of actions and other indexed fields.

Cortellis™ All "programmed cell death ligand 1 inhibitor" Index Full Text Explore en Monica Romero

Advanced search | Structure search | Search history

< Back Forward > Search Results Save and Alert Download

743 results found for index Search for the search term "programmed cell death ligand 1 inhibitor"

Report Type	Results Per page: 25 Sort by: Relevance Order Columns
Show selected only	Report Presentation 743
Broker Research (0)	<input checked="" type="checkbox"/>
Clinical Trials (1811)	<input checked="" type="checkbox"/>
Companies (82)	<input type="checkbox"/>
Conferences (743)	<input checked="" type="checkbox"/>
Deals (272)	<input type="checkbox"/>

A phase I study of TQ-B2450, a PD-L1 mAb, plus anlotinib in EGFR+ advanced NSCLC patients failed to prior EGFR TKI therapies

Conference: 2021 European Lung Cancer Conference Conference Start Date: 25-Mar-2021
Data were presented from an ongoing, phase I study (ChiCTR1900026273) which evaluated the safety and efficacy of TQB-2450 (a humanized programmed death-ligand 1 mAb) plus anlotinib (an antiangiogenic multi-target TKI) in EGFR-positive advanced NSCLC patients who failed prior EGFR TKI therapies. Patients (n = 9) received escalating doses (3 + 3 design) of anlotinib (8, 10, and 12 mg, po) for 2 weeks in a 21-day cycle (days 1 to 14), with TQB-2450 (1200 mg, q3w on day 1). There were no DLTs reported

Conference reports can be searched by title, indication, mechanism of action, chemical structure and more

For more information contact Customer Service at **LS Product Support**